Literature DB >> 21489023

Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence.

Yasuo Okumura1, Ichiro Watanabe, Toshiko Nakai, Kimie Ohkubo, Tatsuya Kofune, Masayoshi Kofune, Koichi Nagashima, Hiroaki Mano, Kazumasa Sonoda, Yuji Kasamaki, Atsushi Hirayama.   

Abstract

INTRODUCTION: Although catheter ablation can effectively eliminate atrial fibrillation (AF), the progression of atrial remodeling increases the risk of recurrence. AF is associated with inflammation and subsequent myocardial fibrosis. We therefore examined the possibility of determining the postablation prognosis of patients with AF using biomarkers of inflammation and collagen turnover. METHODS AND
RESULTS: Subjects were 50 patients who underwent catheter ablation for drug-resistant AF. High-sensitivity CRP (hs-CRP), interleukin (IL)-6, carboxyl-terminal telopeptide of collagen type I (ICTP), metalloproteinase (MMP)-2, tissue inhibitor of MMP-2 (TIMP-2), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) were measured before and 2.2 ± 0.8 months after ablation. During the follow-up period of 14.0 (4.7-20.9) months, AF recurred in 21 of the 50 patients. Recurrence was associated with an MMP-2 elevation (860.3 ± 120.8 ng/mL vs 687.0 ± 122.5 ng/mL [in patients without recurrence]), ICTP elevation (3.2 ± 1.1 ng/mL vs 2.7 ± 0.6 ng/mL), BNP elevation, greater body mass index, nonparoxysmal AF, and hypertension (P < 0.05 for all). Serum MMP-2 and nonparoxysmal AF were shown by multivariate analysis to be independent predictors for postablation AF recurrence. Overall, hs-CRP, IL-6, ANP, and BNP levels decreased, and MMP-2, TIMP-2, and ICTP levels increased 2 months after ablation.
CONCLUSIONS: Our finding that markers of collagen turnover were elevated in patients who experienced AF recurrence after ablation indicate that these markers might be a useful guide to identify a subgroup of AF patients who require extensive ablation strategies. A 2-month postablation elevation in collagen turnover markers suggests that the wound healing process persists for that long after ablation.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21489023     DOI: 10.1111/j.1540-8167.2011.02059.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  29 in total

Review 1.  Impact of metabolic syndrome on the risk of atrial fibrillation recurrence after catheter ablation: systematic review and meta-analysis.

Authors:  Kueiyu Joshua Lin; Soung Ick Cho; Nidhish Tiwari; Michael Bergman; Jorge R Kizer; Eugen C Palma; Cynthia C Taub
Journal:  J Interv Card Electrophysiol       Date:  2013-12-19       Impact factor: 1.900

2.  Galectin 3 and incident atrial fibrillation in the community.

Authors:  Jennifer E Ho; Xiaoyan Yin; Daniel Levy; Ramachandran S Vasan; Jared W Magnani; Patrick T Ellinor; David D McManus; Steven A Lubitz; Martin G Larson; Emelia J Benjamin
Journal:  Am Heart J       Date:  2014-03-01       Impact factor: 4.749

Review 3.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

Review 4.  Role of inflammation in atrial fibrillation pathophysiology and management.

Authors:  Masahide Harada; David R Van Wagoner; Stanley Nattel
Journal:  Circ J       Date:  2015-02-16       Impact factor: 2.993

5.  Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Authors:  Naoko Sasaki; Yasuo Okumura; Ichiro Watanabe; Hiroaki Mano; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

Review 6.  The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy.

Authors:  Yehuda Edo Paz; Sabahat Bokhari
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-30       Impact factor: 2.357

7.  Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation.

Authors:  Michael F Swartz; Gregory W Fink; Muhammad F Sarwar; George L Hicks; Yao Yu; Rui Hu; Charles J Lutz; Steven M Taffet; José Jalife
Journal:  J Am Coll Cardiol       Date:  2012-10-30       Impact factor: 24.094

Review 8.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

Review 9.  [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].

Authors:  Jelena Kornej; Katja Schumacher; Daniela Husser; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

10.  Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation.

Authors:  Yoshizumi Takei; Minoru Ichikawa; Yoshiyuki Kijima
Journal:  J Arrhythm       Date:  2014-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.